Cargando…

Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma

BACKGROUND: Zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing proteins have been reported to be associated with many tumors’ development. However, in tumor initiation and progression, the role of ZBTB9, one of the protein family, and its prognostic value were yet to be elucidated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenshan, Wu, Leilei, Li, Juan, Chen, Jiayan, Yu, Qi, Yao, Hui, Xu, Yaping, Liu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756481/
https://www.ncbi.nlm.nih.gov/pubmed/36522647
http://dx.doi.org/10.1186/s12967-022-03790-0
_version_ 1784851638637297664
author Zhang, Zhenshan
Wu, Leilei
Li, Juan
Chen, Jiayan
Yu, Qi
Yao, Hui
Xu, Yaping
Liu, Liang
author_facet Zhang, Zhenshan
Wu, Leilei
Li, Juan
Chen, Jiayan
Yu, Qi
Yao, Hui
Xu, Yaping
Liu, Liang
author_sort Zhang, Zhenshan
collection PubMed
description BACKGROUND: Zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing proteins have been reported to be associated with many tumors’ development. However, in tumor initiation and progression, the role of ZBTB9, one of the protein family, and its prognostic value were yet to be elucidated in Liver Hepatocellular Carcinoma (LIHC). METHODS: We used R software and online bioinformatics analysis tools such as GEPIA2, cBioPortal, TIMER2, Metascape, UALCAN, STRING, TISIDB, and COSMIC to investigate ZBTB9’s characteristics and function in LIHC, including abnormal expression, carcinogenic role, related signaling pathways and prognostic value. Furthermore, cell experiments (such as formation, wound healing, and transwell assays) and analyses based on clinical samples (such as immunohistochemistry (IHC) and promoter methylation analysis) were conducted to verify pivotal conclusions. RESULTS: ZBTB9 was overexpressed in LIHC samples compared to adjacent normal tissues. Through the analysis of genomic alteration and promoter hypomethylation, the clinical value and etiology of abnormal expression of ZBTB9 were preliminarily exlpored. Subsequent evidence showed that it could result in tumor progression and poor prognosis via activating cell cycle, DNA repair, MYC, and KRAS-associated signaling pathways as well as rendering immune dysregulation. After the knockdown of ZBTB9, evidently inhibited capacities of tumor cells proliferation and migration were observed. These results together indicated that ZBTB9 could be a promising prognostic biomarker and had the potential value to offer novel therapeutic targets for LIHC treatment. CONCLUSIONS: ZBTB9 was identified as a novel biomarker to predict the prognosis and tumor progression in LIHC, and a promising therapeutic target to invert tumor development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03790-0.
format Online
Article
Text
id pubmed-9756481
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97564812022-12-17 Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma Zhang, Zhenshan Wu, Leilei Li, Juan Chen, Jiayan Yu, Qi Yao, Hui Xu, Yaping Liu, Liang J Transl Med Research BACKGROUND: Zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing proteins have been reported to be associated with many tumors’ development. However, in tumor initiation and progression, the role of ZBTB9, one of the protein family, and its prognostic value were yet to be elucidated in Liver Hepatocellular Carcinoma (LIHC). METHODS: We used R software and online bioinformatics analysis tools such as GEPIA2, cBioPortal, TIMER2, Metascape, UALCAN, STRING, TISIDB, and COSMIC to investigate ZBTB9’s characteristics and function in LIHC, including abnormal expression, carcinogenic role, related signaling pathways and prognostic value. Furthermore, cell experiments (such as formation, wound healing, and transwell assays) and analyses based on clinical samples (such as immunohistochemistry (IHC) and promoter methylation analysis) were conducted to verify pivotal conclusions. RESULTS: ZBTB9 was overexpressed in LIHC samples compared to adjacent normal tissues. Through the analysis of genomic alteration and promoter hypomethylation, the clinical value and etiology of abnormal expression of ZBTB9 were preliminarily exlpored. Subsequent evidence showed that it could result in tumor progression and poor prognosis via activating cell cycle, DNA repair, MYC, and KRAS-associated signaling pathways as well as rendering immune dysregulation. After the knockdown of ZBTB9, evidently inhibited capacities of tumor cells proliferation and migration were observed. These results together indicated that ZBTB9 could be a promising prognostic biomarker and had the potential value to offer novel therapeutic targets for LIHC treatment. CONCLUSIONS: ZBTB9 was identified as a novel biomarker to predict the prognosis and tumor progression in LIHC, and a promising therapeutic target to invert tumor development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03790-0. BioMed Central 2022-12-15 /pmc/articles/PMC9756481/ /pubmed/36522647 http://dx.doi.org/10.1186/s12967-022-03790-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Zhenshan
Wu, Leilei
Li, Juan
Chen, Jiayan
Yu, Qi
Yao, Hui
Xu, Yaping
Liu, Liang
Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title_full Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title_fullStr Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title_full_unstemmed Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title_short Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma
title_sort identification of zbtb9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in liver hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756481/
https://www.ncbi.nlm.nih.gov/pubmed/36522647
http://dx.doi.org/10.1186/s12967-022-03790-0
work_keys_str_mv AT zhangzhenshan identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT wuleilei identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT lijuan identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT chenjiayan identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT yuqi identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT yaohui identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT xuyaping identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma
AT liuliang identificationofzbtb9asapotentialtherapeutictargetagainstdysregulationoftumorcellsproliferationandanovelbiomarkerinliverhepatocellularcarcinoma